Citigroup Maintains Buy on Cabaletta Bio, Lowers Price Target to $8
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Samantha Semenkow maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and lowers the price target from $10 to $8.
Citigroup analyst Samantha Semenkow maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and lowers the price target from $10 to $8.